Mission Creek Capital Partners Inc. Buys New Position in Pfizer Inc. (NYSE:PFE)

Mission Creek Capital Partners Inc. bought a new stake in shares of Pfizer Inc. (NYSE:PFE) in the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 10,183 shares of the biopharmaceutical company’s stock, valued at approximately $270,000.

A number of other hedge funds also recently modified their holdings of the company. Rinkey Investments lifted its position in shares of Pfizer by 24.7% in the 4th quarter. Rinkey Investments now owns 9,191 shares of the biopharmaceutical company’s stock worth $244,000 after acquiring an additional 1,823 shares during the period. Aquatic Capital Management LLC grew its holdings in Pfizer by 96.3% during the 4th quarter. Aquatic Capital Management LLC now owns 241,877 shares of the biopharmaceutical company’s stock worth $6,417,000 after acquiring an additional 118,677 shares during the last quarter. Oxford Asset Management LLP bought a new stake in Pfizer during the 4th quarter worth about $729,000. Bolthouse Investments LLC bought a new stake in Pfizer during the 4th quarter worth about $220,000. Finally, Boothbay Fund Management LLC bought a new stake in Pfizer during the 4th quarter worth about $1,335,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE PFE opened at $22.95 on Monday. The stock has a market cap of $130.16 billion, a PE ratio of 16.28, a P/E/G ratio of 0.64 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The firm has a 50-day moving average of $24.58 and a 200-day moving average of $25.92. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the prior year, the business earned $0.10 EPS. Pfizer’s quarterly revenue was up 24.7% on a year-over-year basis. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.49%. Pfizer’s payout ratio is presently 121.99%.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. The Goldman Sachs Group reissued a “neutral” rating and set a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. UBS Group cut their price target on shares of Pfizer from $28.00 to $24.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 8th. Finally, Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating, five have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, Pfizer has a consensus rating of “Moderate Buy” and an average price target of $29.57.

Insiders Place Their Bets

In other news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 0.06% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.